Clinical Trial Update: Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update indicates Gedatolisib plus Fulvestrant, with or without Palbociclib, is active but not recruiting for advanced or metastatic HR+…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• Fulvestrant (fulvestrant)
• Gedatolisib (gedatolisib)
• Palbociclib (palbociclib)

Snippet

Sponsor: Celcuity Inc | Conditions: Breast Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING